In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company ...
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn ...
Fintel reports that on February 28, 2025, William Blair initiated coverage of BioAge Labs (NasdaqGS:BIOA) with a Market ...
SAN FRANCISCO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial.
On or about September 2024, BioAge conducted its IPO, selling 12.65 million shares of stock for $18 per share. On December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES ...
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of the March 10, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf ...
RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc.
Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, March 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law ...
LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against BioAge Labs ...
SAN FRANCISCO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who ...